For research use only. Not for therapeutic Use.
Miltefosine（Cat No.:A000585）is an alkylphosphocholine compound originally developed as an anticancer agent, now primarily used as an antiparasitic drug. It is effective against Leishmaniasis, a protozoan infection, and is the first oral drug approved for treating visceral, cutaneous, and mucocutaneous leishmaniasis. Miltefosine acts by disrupting cell membrane integrity and signaling pathways, leading to apoptosis in parasites. Additionally, it shows activity against amoebic infections like Acanthamoeba and Naegleria fowleri. Miltefosine’s broad antiparasitic spectrum makes it a vital tool in combating neglected tropical diseases.
| Catalog Number | A000585 |
| CAS Number | 58066-85-6 |
| Synonyms | Hexadecylphosphocholine |
| Molecular Formula | C21H46NO4P |
| Purity | ≥95% |
| Target | Akt |
| Solubility | Limited solubility |
| Storage | Store at -20C |
| Related CAS | 93597-88-7 |
| Overview of Clinical Research | Miltefosine is a signal transduction pathway inhibitor. It received the orphan drug status<span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”> <span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>for Granulomatous amebic encephalitis in USA in 2017.</span></span></span> |
| IUPAC Name | hexadecyl 2-(trimethylazaniumyl)ethyl phosphate |
| InChI | InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3 |
| InChIKey | PQLXHQMOHUQAKB-UHFFFAOYSA-N |
| SMILES | CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C |
| Reference | 1: Reinhardt M, Heyl P, Amelung F, Berger MR. Effect of miltefosine on transplanted methylnitrosourea-induced mammary carcinoma growing in Fischer 344 rats. Arzneimittelforschung. 1992 Oct;42(10):1239-42. PubMed PMID: 1282010.<br /> |
